North America Genetic Testing Market
市场规模（十亿美元）
CAGR :
% 
USD
5,688.94 Billion
USD
17,887.74 Billion
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 5,688.94 Billion |
 Market Size (Forecast Year) |
USD 17,887.74 Billion |
 CAGR |
% |
| Major Markets Players |
North America Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, Prenatal Testing, New Born Screening, Predictive And Presymptomatic Testing, Other Types), Technology (DNA Sequencing (NGS-Based Testing), Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), Others), Diseases (Rare Genetic Disorder, CancerCystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Duchenne Muscular Dystrophy, Others) End User (Hospitals, Clinics, Diagnostic Centres, Private Clinics, Laboratory Service Providers, Private Laboratories) Industry Trends and Forecast to 2029
Market Analysis and Insights
North America genetic testing market is driven by the factors such as the high prevalence of genetic disorders, growing technological advancements in the genetic testing market which enhance its demand, as well as increasing investment in research and development, which leads to market growth. Currently, healthcare expenditure has increased across developed and emerging countries which is expected to create a competitive advantage for manufacturers to develop new and innovative genetic testing markets. However, the high cost associated with genetic testing and stringent regulatory frameworks for genetic testing.
North America genetic testing market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various region and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
Market Definition
Genetic testing is a kind of medical test that identifies changes in genes, chromosomes, or proteins. The outcome of a genetic test can confirm or rule out a suspected genetic condition or aid in determining a person’s chance of developing or passing on a genetic disorder. Over 77,000 genetic tests are currently in use, and others are being developed.
The increasing innovations and technologies and rising number of players in the market, and novel product launches are also propelling the growth of the North America genetic testing market.
北美基因检测市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场以 15.6% 的复合年增长率增长，预计将从 2021 年的 56.8894 亿美元达到 2029 年的 178.8774 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按类型（携带者检测、诊断检测、产前检测、新生儿筛查、预测性和症状前检测、其他类型）、技术（DNA 测序（基于 NGS 的检测）、聚合酶链反应、微阵列、全基因组测序、荧光原位杂交 (FISH)、其他）、疾病（罕见遗传病、癌症、囊性纤维化、镰状细胞性贫血、杜氏肌营养不良症、地中海贫血、亨廷顿氏病、脆性 X 综合征、杜氏肌营养不良症、其他）最终用户（医院、诊所、诊断中心、私人诊所、实验室服务提供商、私人实验室） |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
Thermo Fisher Scientific Inc.、Invitae Corporation、Bio-Rad Laboratories, Inc.、PerkinElmer Inc.、Illumina, Inc.、QIAGEN、F. Hoffmann-La Roche Ltd.、Fulgent Genetics、Myriad Genetics, Inc.、Abbott、Eurofins Scientific、Sorenson Genomics、Biocartis、Cepheid（Danaher 的子公司）、PacBio、Otogenetics、BioReference、Sema4 OpCo, Inc.、Natera, Inc. 等 |
北美基因检测市场动态
驱动程序
-
遗传疾病的患病率不断上升
遗传性疾病可能导致严重的健康问题，甚至无法生存。在最严重的情况下，这些疾病可能会导致受影响的胚胎或胎儿流产。遗传疾病和出生缺陷的患病率不断上升，推动了对基因检测的需求
根据文章《遗传性疾病和先天性畸形：减轻该地区负担的策略，2022 年》，
-
约 2%-5% 的活产婴儿患有遗传性疾病和先天畸形，这占儿科住院人数的 30%，并导致工业化国家约 50% 的儿童死亡
因此，这增加了基因检测市场的需求。
-
下一代测序的采用率增加
随着以基因组学为重点的药理学在各种慢性疾病（尤其是癌症）的治疗中发挥着越来越重要的作用，下一代测序（NGS）正在发展成为一种强有力的工具，可以更深入、更精确地了解个体肿瘤和特定受体的分子基础。
与传统方法相比，NGS 在准确性、灵敏度和速度方面具有优势，有望对肿瘤学领域产生重大影响。由于 NGS 可以在一次检测中评估多个基因，因此无需进行多次检测来确定致病突变。
例如，
-
NGS 还被用于对与药物药代动力学和药效学相关的药物遗传学进行全面分析，2017 年的初步报告表明，该技术可能是一种可靠有效的工具，可以发现这些基因中常见和罕见的遗传变异。
因此，这有望成为基因检测市场增长的推动力。
机会
-
可支配收入增加
一个国家在医疗保健方面的支出及其随时间的增长速度受到各种经济和社会因素的影响，包括医疗系统的融资安排和组织结构。特别是，一个国家的整体收入水平与该国人口在医疗保健方面的支出之间存在着密切的联系。
此外，主要市场参与者采取的战略举措将为 2022-2029 年预测期内的基因检测市场提供结构完整性和未来机会。
限制/挑战
- 基因检测成本高昂
基因检测费用昂贵，而且有些健康保险计划可能不予报销。多种基因检测的费用因检测的目标疾病而异。
根据Breastcancer.org，癌症基因检测的费用差异很大，可能在300美元到5000美元之间。基因检测的费用取决于检测类型以及检测的复杂程度。
基因检测的费用从 100 美元到 2,000 美元不等，具体取决于检测的性质和复杂程度。如果需要进行多项检测或必须对多名家庭成员进行检测才能获得有意义的结果，费用就会增加。新生儿筛查的费用因州而异。
Covid-19 对北美基因检测市场的影响
COVID-19 对市场产生了积极影响，因为针对 COVID-19 进行了许多基因和血清学测试，这增加了这一时期对基因检测的需求。
近期发展
- 2021 年 12 月，赛默飞世尔科技公司宣布以 174 亿美元完成对 PPD, Inc. 的收购，后者是生物制药和生物技术行业领先的全球临床研究服务提供商。此次收购有助于创造更多收入并促进市场增长。
北美基因检测市场范围
北美基因检测市场分为类型、技术、疾病和最终用户。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
类型
- 诊断测试
- 产前检查
- 新生儿筛查
- 预测性和症状前检测
- 携带者检测
- 其他类型
根据类型，北美基因检测市场分为诊断检测、产前检测、新生儿筛查、预测和症状前检测、携带者检测和其他类型。
技术
- 聚合酶链式反应
- DNA 测序（基于 NGS 的检测）
- 全基因组测序
- 微阵列
- 荧光原位杂交 (FISH)
- 其他的
根据技术，北美基因检测市场分为 DNA 测序（基于 NGS 的检测）、聚合酶链反应、微阵列、全基因组测序、荧光原位杂交 (FISH) 和其他。
疾病
- 癌症
- 镰状细胞性贫血
- 地中海贫血
- 罕见遗传病
- 脆性 X 综合征
- 杜氏肌营养不良症
- 亨廷顿氏病
- 囊性纤维化
- 其他的
根据疾病，北美基因检测市场细分为罕见遗传病、癌症、囊性纤维化、镰状细胞性贫血、杜氏肌营养不良症、地中海贫血、亨廷顿氏病、脆性X 综合征等。
最终用户
- 医院
- 诊所
- 诊断中心
- 私人诊所
- 实验室服务提供商
- 私人实验室
根据最终用户，北美基因检测市场细分为医院、诊所、诊断中心、私人诊所、实验室服务提供商、私人实验室。
基因检测市场区域分析/见解
对基因检测市场进行了分析，并按国家、类型、技术、疾病和最终用户提供了市场规模洞察和趋势。
由于美国人口中遗传疾病的患病率不断上升，美国成为该市场的主要主导国家。他们在市场份额和市场收入方面占据基因检测市场的主导地位，并将在预测期内继续保持主导地位。这是由于这些地区人口中存在遗传缺陷和染色体畸变，而快速的研究发展正在推动市场的发展。
报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和基因检测市场份额分析
基因检测市场竞争格局提供了有关竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对基因检测市场的关注有关。
基因检测市场的一些主要参与者包括赛默飞世尔科技公司 (Thermo Fisher Scientific Inc.)、Invitae Corporation、Bio-Rad Laboratories, Inc.、PerkinElmer Inc.、Illumina, Inc.、QIAGEN、F. Hoffmann-La Roche Ltd.、Fulgent Genetics、Myriad Genetics, Inc.、Abbott、Eurofins Scientific、Sorenson Genomics、Biocartis、Cepheid（丹纳赫的子公司）、PacBio、Otogenetics、BioReference、Sema4 OpCo, Inc.、Natera, Inc. 等
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 STRATEGIC INITIATIVES:
4.4 CONCLUSION:
4.5 INDUSTRY INSIGHTS
4.5.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
4.5.2 GENETIC TESTS PRICING
4.5.3 KEY INSIGHTS
5 EPIDERMIOLOGY
6 NORTH AMERICA GENETIC TESTING MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER
7.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
7.2 RESTRAINTS
7.2.1 HIGH COST OF GENETIC TESTING
7.2.2 CYBER SECURITY CONCERNS IN GENOMICS
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
7.3.2 TECHNOLOGICAL ADVANCEMENT
7.3.3 INCREASING RESEARCH AND DEVELOPMENT
7.3.4 RISING DISPOSABLE INCOME
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
7.4.2 STRINGENT REGULATION POLICY
8 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC TESTING
8.3 PRENATAL TESTING
8.3.1 NON-INVASIVE SCREENING
8.3.1.1 BY SCREENING METHOD
8.3.1.1.1 WHOLE GENOME SEQUENCING
8.3.1.1.2 COUNTING OF cfDNA FRAGMENTS
8.3.1.1.3 OTHERS
8.3.1.2 BY CONDITION
8.3.1.2.1 TRISOMY 21
8.3.1.2.2 KLINEFELTER SYNDROME
8.3.1.2.3 JACOBS SYNDROME
8.3.1.2.4 CYSTIC FIBROSIS
8.3.1.2.5 TURNER SYNDROME
8.3.1.2.6 TRISOMY 18
8.3.1.2.7 HEMOPHILIA
8.3.1.2.8 TRISOMY 13
8.3.1.2.9 MICRODELETION SYNDROME
8.3.1.2.10 FETAL GENDER
8.3.1.2.11 OTHERS
8.3.1.3 BY SCREENING TYPE
8.3.1.3.1 CARRIER SEQUENCING
8.3.1.3.2 SEQUENTIAL SEQUENCING
8.3.2 MATERNAL SERUM QUAD SCREENING
8.4 NEW BORN SCREENING
8.4.1.1 SICKLE CELL DISEASE
8.4.1.2 CONGENITAL HYPOTHYROIDISM
8.4.1.3 PHENYLKETONURIA (PKU)
8.4.1.4 GALACTOSEMIA
8.4.1.5 MAPLE SYRUP URINE DISEASE
8.4.1.6 OTHERS
8.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
8.6 CARRIER TESTING
8.6.1 BY TEST TYPE
8.6.1.1 MOLECULAR SCREENING TEST
8.6.1.2 BIOCHEMICAL SCREENING TEST
8.6.2 BY TYPE
8.6.2.1 EXPANDED CARRIER SCREENING
8.6.2.1.1 PREDESIGNED PANEL TESTING
8.6.2.1.2 CUSTOM-MADE PANEL TESTING
8.6.2.2 TARGETED DISEASE CARRIER SCREENING
8.6.2.2.1 BY MEDICAL CONDITION
8.6.2.2.2 HEMATOLOGICAL CONDITIONS
8.6.2.2.3 PULMONARY CONDITIONS
8.6.2.2.4 NEUROLOGICAL CONDITIONS
8.6.2.2.5 OTHER CONDITIONS
8.7 OTHER TYPES
9 NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION
9.2.1 REAL-TIME PCR (QPCR)
9.2.2 DIGITAL PCR (DPCR)
9.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
9.2.4 HOT-START PCR
9.2.5 MULTIPLEX PCR
9.2.6 OTHER PCR
9.3 DNA SEQUENCING (NGS-BASED TESTING)
9.3.1 NEXT GENERATION SEQUENCING (NGS)
9.3.2 SANGER SEQUENCING (SINGLE GENE)
9.3.3 OTHER
9.4 WHOLE GENOME SEQUENCING
9.5 MICROARRAYS
9.5.1 DNA MICROARRAYS
9.5.2 PROTEIN MICROARRAYS
9.5.3 OTHER MICROARRAYS
9.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
9.7 OTHERS
10 NORTH AMERICA GENETIC TESTING MARKET, BY DISEASES
10.1 OVERVIEW
10.2 CANCER
10.2.1 BREAST
10.2.2 COLON
10.2.3 LUNG
10.2.4 PROSTATE
10.2.5 OTHERS
10.3 SICKLE CELL ANEMIA
10.4 THALASSEMIA
10.5 RARE GENETIC DISORDER
10.5.1 TRISOMY 21
10.5.2 MONOSOMY X
10.5.3 TRISOMY 13
10.5.4 MICRODELETION SYNDROME
10.5.5 TRISOMY 18
10.5.6 OTHERS
10.6 FRAGILE X SYNDROME
10.7 DUCHENNE MUSCULAR DYSTROPHY
10.8 HUNTINGTON'S DISEASE
10.9 CYSTIC FIBROSIS
10.1 OTHERS
11 NORTH AMERICA GENETIC TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 PRIVATE CLINICS
11.6 LABORATORY SERVICE PROVIDERS
11.7 PRIVATE LABORATORIES
12 NORTH AMERICA GENETIC TESTING MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA GENETIC TESTING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 ILLUMINA, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.1.4.1 ACQUISITION
15.1.4.2 COLLABORATION
15.2 CEPHEID
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 BUSINEES EXPANSION
15.3 FULGENT GENETICS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 PERKINELMER INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.4.5.1 PRODUCT LAUNCH
15.5 THERMO FISHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.5.5.1 COLLABORATION
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIOCARTIS
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.7.4.1 PARTNERSHIP
15.7.4.2 AGREEMENT
15.8 BIO-HELIX
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 ACQUISITION
15.9.4.2 PARTNERSHIP
15.1 BIOREFERENCE
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.10.4.1 ACQUISITION
15.11 ELITECHGROUP
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.11.3.1 PRODUCT LAUNCH
15.11.3.2 BUSINESS EXPANSION
15.12 EUROFINS SCIENTIFIC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.12.4.1 PRODUCT LAUNCH
15.13 EUGENE LABS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 F. HOFFMANN-LA ROCHE LTD)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS (PARENT COMPANY)
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.14.4.1 PRODUCT LAUNCH
15.15 GENES2ME
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INVITAE CORPORATION
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 MAPMYGENOME
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 MEDGENOME
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 MYRIAD GENETICS
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 NATERA, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 PARTNERSHIP
15.21 OTOGENRTICS
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.22 PACBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENT
15.23 QIAGEN
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 PARTNERSHIP
15.23.3.2 PRODUCT LAUNCH
15.24 SEMA4 OPCO, INC.
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
15.25 SORENSON GENOMICS
15.25.1 COMPANY SNAPSHOT
15.25.2 PRODUCT PORTFOLIO
15.25.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 3 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 4 NORTH AMERICA DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 8 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 9 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 11 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 12 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 15 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 16 NORTH AMERICA NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 22 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 23 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 25 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 26 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 28 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 29 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA CANCER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 57 NORTH AMERICA PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 58 NORTH AMERICA LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA GENETIC TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 61 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 63 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 64 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 66 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 67 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 68 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 69 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 70 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 71 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 72 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 73 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 74 NORTH AMERICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 76 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 77 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 78 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 80 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 81 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 83 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 84 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 85 NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 86 NORTH AMERICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 87 NORTH AMERICA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 NORTH AMERICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 NORTH AMERICA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 90 NORTH AMERICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 91 NORTH AMERICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 92 NORTH AMERICA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.S. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 U.S. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 95 U.S. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 96 U.S. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.S. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 98 U.S. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 99 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 100 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 101 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 102 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 103 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 104 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 105 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 106 U.S. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 108 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 109 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 110 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 112 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 113 U.S. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 U.S. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 115 U.S. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 116 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 117 U.S. GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 U.S. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 119 U.S. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 120 U.S. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 121 U.S. GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 122 U.S. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 123 U.S. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 124 U.S. GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 125 CANADA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 CANADA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 127 CANADA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 128 CANADA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 CANADA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 130 CANADA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 131 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 132 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 133 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 134 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 135 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 136 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 137 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 138 CANADA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 140 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 141 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 142 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 144 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 145 CANADA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 CANADA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 147 CANADA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 148 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 149 CANADA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 150 CANADA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 CANADA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 152 CANADA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 153 CANADA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 154 CANADA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 155 CANADA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 156 CANADA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 MEXICO GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 MEXICO GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 159 MEXICO GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 160 MEXICO PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 MEXICO PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 162 MEXICO PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 163 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 164 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 165 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 166 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 167 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 168 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 169 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 170 MEXICO NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 172 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 173 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 174 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 176 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 177 MEXICO EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 MEXICO EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 179 MEXICO EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 180 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 181 MEXICO GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 182 MEXICO POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 183 MEXICO DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 184 MEXICO MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 185 MEXICO GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 186 MEXICO RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 187 MEXICO CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 188 MEXICO GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA GENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA GENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA GENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA GENETIC TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA GENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA GENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA GENETIC TESTING MARKET: APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA GENETIC TESTING MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GENETIC TESTING MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA GENETIC TESTING MARKET
FIGURE 15 NORTH AMERICA GENETIC TESTING MARKET: BY TYPE, 2021
FIGURE 16 NORTH AMERICA GENETIC TESTING MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 17 NORTH AMERICA GENETIC TESTING MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 NORTH AMERICA GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2021
FIGURE 20 NORTH AMERICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 21 NORTH AMERICA GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 22 NORTH AMERICA GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 23 NORTH AMERICA GENETIC TESTING MARKET: BY DISEASES, 2021
FIGURE 24 NORTH AMERICA GENETIC TESTING MARKET: BY DISEASES, 2022-2029 (USD MILLION)
FIGURE 25 NORTH AMERICA GENETIC TESTING MARKET: BY DISEASES, CAGR (2022-2029)
FIGURE 26 NORTH AMERICA GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 27 NORTH AMERICA GENETIC TESTING MARKET: BY END USER, 2021
FIGURE 28 NORTH AMERICA GENETIC TESTING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 NORTH AMERICA GENETIC TESTING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 NORTH AMERICA GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 NORTH AMERICA GENETIC TESTING MARKET: SNAPSHOT (2021)
FIGURE 32 NORTH AMERICA GENETIC TESTING MARKET: BY COUNTRY (2021)
FIGURE 33 NORTH AMERICA GENETIC TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 34 NORTH AMERICA GENETIC TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 35 NORTH AMERICA GENETIC TESTING MARKET: BY TYPE (2022-2029)
FIGURE 36 NORTH AMERICA GENETIC TESTING MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
